Proportion of sodium-glucose co-transporter 2 (SGLT-2) inhibitors (including combination products) not prescribed as generic dapagliflozin tablets by all Sub-ICB Locations
Why it matters:
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor commonly prescribed in type 2 diabetes, the treatment of chronic heart failure, and chronic kidney disease.
Dapagliflozin lost its patent in August 2025. From September 2025 the NHS tariff price is likely to fall, as it will be based on the generic price, rather than the branded product. NICE guidance on the treatment of diabetes states that if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost. Dapagliflozin is likely to have cost-saving opportunities when compared with other SGLT-2s.
Please note: OpenPrescribing.net measures have a consistent way of visualising measures, where 'lower is better' and therefore in this case we show the proportion of SGLT-2 inhibitors which are NOT prescribed as generic dapagliflozin tablets.
Description: Percentage SGLT-2 inhibitors items not prescribed as generic dapagliflozin tablets
Explore:
Tagged as: Diabetes, Standard, Cost Saving (or browse all measures)
Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.
View measure for NHS England combined →
Fetching data...